good news!The price is about to be reduced

The seventh batch of national organizational drug collection was opened in Nanjing, Jiangsu on the 12th. This time, there are 60 varieties, involving common diseases such as hypertension, diabetes, anti -infection, and digestive tract diseases, chronic diseases, lung cancer, liver cancer, kidney cancer, and bowel cancer.

not

327 products are planned to be selected in this collection, and the average price reduction of the selected products is 48%. According to the agreed purchase volume, it is expected to save 18.5 billion yuan per year.

not

It is understood that this collection is calculated according to the agreed purchase volume, and it is expected to save 18.5 billion yuan per year.

Specifically, this collection of drugs involves 31 treatment categories, including common diseases such as hypertension, diabetes, anti -infection, digestive tract diseases, and major diseases such as lung cancer, liver cancer, kidney cancer, and bowel cancer. The benefit is wide and strong. Taking the first -line liver cancer -targeted Yaolunbutoni capsule as an example, each drop from an average of 108 yuan to an average of 18 yuan, and a healing cycle can save 8,100 yuan. For the first time in the field of lowering blood pressure, it was included in the slow -controlled release agent. The price of nifeding horizontal control was 58%reduced, and the price of Matolol's slow -release tablet was 53%. The burden on the medication of patients with hypertension was significantly reduced. Anti -virus drug Osdivir's per tablet decreased from 4.5 yuan to 1 yuan. In addition, Pfizer's Donalin, Japan's Anstelai Mikafen Pure, Emmiro of Spain, Emmoro, and Bryko Xinyi, Italy, 4 original research medicines In the election, the average price was reduced by 67%.

In terms of procurement rules, this collection adheres to the basic principles of "linked and priced, recruiting one" and "national organization, alliance procurement, platform operation" working mechanism, and make further adjustments and optimizations to strengthen supply guarantees. For the first time, the province will be introduced. Each province will have one main company and one for enterprises to ensure stable clinical use.

It is understood that since the establishment of the State Medical Insurance Bureau in 2018, it has carried out seven batches of centralized procurement of drugs for national organizations, covering a total of 294 kinds of drugs. According to the pre -mining price, the amount involved in the amount of chemical drugs and biopharmaceutical procurement of public medical institutions involved in the amount of public medical institutions. 35%, concentrated band procurement has become an important model for drug procurement of public hospitals. In the next step, the National Medical Insurance Administration will work with relevant departments to guide the implementation of the selection results in various places and middle school companies to ensure that patients across the country use the selected products after the collection of prices in November 2022.

Source: Xinhua News Agency, Yangguang.com

- END -